CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
推进胶质母细胞瘤治疗中基于疫苗的免疫疗法
英文原题：Advancing vaccine-based immunotherapy in glioblastoma treatment.
查看英文原题
Advancing vaccine-based immunotherapy in glioblastoma treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）起源于胶质细胞，以侵袭性生长和预后不良为特征。尽管手术切除技术不断进步，完全清除肿瘤仍然具有挑战性，常导致复发并对标准治疗产生耐药。免疫治疗和传统治疗在提高多种癌症的治疗效果方面显示出前景。研究人员持续探索新的治疗方法，尤其是放疗、化疗和手术；然而，胶质母细胞瘤仍然极具挑战性，生存期改善有限。免疫治疗的最新进展，特别是肿瘤疫苗如肽基疫苗和细胞基疫苗（例如树突状细胞疫苗），代表了重大进步，尽管当前临床试验中仍存在局限性。本文综述了基于疫苗的免疫治疗在胶质母细胞瘤治疗中的最新进展。
展开英文摘要原文
Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers.
Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials. This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.
论文信息
- 作者
- Singh DD、Haque S、Singh AK、Yadav DK
- 第一作者单位
- Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India.India
- 通讯作者单位
- Department of Biologics, College of Pharmacy, Gachon University, Yeonsu-gu, Incheon, Republic of Korea.South Korea
- 文献类型
- 综述
- 期刊
- Neuro-oncology advances2025 Jan-Dec
- 原文标识
- PubMed 40756669 · DOI 10.1093/noajnl/vdaf135
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →